Viking Therapeutics (VKTX) Total Liabilities (2014 - 2026)

Viking Therapeutics has disclosed Total Liabilities across 13 years of filings, most recently posting $106.3 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $106.3 million, up 429.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.3 million (up 429.64% YoY), and the FY2025 annual result was $76.7 million, up 173.39% from the prior year.
• Total Liabilities came in at $106.3 million for Q1 2026 at Viking Therapeutics, up from $76.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $106.3 million in Q1 2026 to a low of $12.8 million in Q1 2022.
• The 5-year median for Total Liabilities is $23.2 million (2022), against an average of $30.0 million.
• Across the five-year window, Total Liabilities plunged 40.3% in 2025 and jumped 429.64% in 2026, its largest moves.
• Viking Therapeutics' Total Liabilities stood at $23.2 million in 2022, then retreated by 13.51% to $20.1 million in 2023, then surged by 39.72% to $28.0 million in 2024, then jumped by 173.39% to $76.7 million in 2025, then jumped by 38.68% to $106.3 million in 2026.
• The last three Total Liabilities figures came in at $106.3 million (Q1 2026), $76.7 million (Q4 2025), and $26.4 million (Q3 2025), per Business Quant data.